A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Sponsor: Danish Breast Cancer Cooperative Group
Listed as NCT00171704, this PHASE3 trial focuses on Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women and remains completed. Sponsored by Danish Breast Cancer Cooperative Group, it has been updated 9 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Mar 2017 [monthly]
Completed PHASE3
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Danish Breast Cancer Cooperative Group
- Novartis Pharmaceuticals
- University of Sheffield
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Copenhagen, Denmark , Esbjerg, Denmark , Herlev, Denmark , Herning, Denmark , Hillerød, Denmark , Kløvervænget, Denmark , Roskilde, Denmark , Sheffield, United Kingdom and 3 more locations